Introduction {#s1}
============

*Klebsiella pneumoniae* (KP) is one of the most common pathogens of nosocomial infections that often cause severe or fatal infections ([@B6]; [@B33]). Carbapenems are currently the most effective beta-lactam antibiotics for the treatment of such severe bacterial infections. With the overuse of carbapenems in clinical treatment over the past decade, the emergence of carbapenem-resistant *K. pneumoniae* (CRKP) has become the main cause of the failure of clinical anti-infective treatment ([@B4]; [@B5]; [@B37]). It is worth noting that extensively drug-resistant *K. pneumoniae* (XDR-KP), which has a broader spectrum of drug resistance than CRKP, should be paid more attention. Because XDR-KP is resistant to most of the antibiotics currently used in the clinic and is only sensitive to tigecycline and polymyxin B, it further reduces the types of drugs available in the clinic, which poses a serious challenge to clinical anti-infective treatment ([@B12]; [@B32]; [@B38]).

High morbidity and mortality are closely related to infection with XDR-KP, with a mortality rate of approximately 40--50% ([@B22]; [@B54]). Currently, colistin is one of the few effective antibiotics in the treatment of XDR-KP infection, and the therapeutic options for infections are extremely limited. However, with the emergence of *mcr-1*-positive *Klebsiella pneumoniae*, which may lead to resistance to colistin, the treatment of XDR-KP infection is increasingly difficult ([@B45]; [@B41]). In addition, because carbapenem genes and other resistance genes can be transmitted frequently through mobile DNA elements, the increasing incidence of XDR-KP infection reported worldwide reflects a serious threat to public health and has even caused fatal outcomes in vulnerable patients. Therefore, it is necessary to explore the molecular epidemiology of and risk factors for infections with XDR-KP ([@B11]; [@B30]; [@B34]).

At present, there have been no reports on the molecular epidemiology and risk factors for XDR-KP infection in Southwestern China. In this retrospective study, we attempted to analyze the clinical characteristics, molecular epidemiology and risk factors for XDR-KP infection collected from Chongqing Renji Affiliated Hospital of the Chinese Academy of Sciences University to provide a theoretical basis for the clinical diagnosis, treatment and control of the spread of XDR-KP infection. Moreover, predictors for mortality in patients with XDR-KP infection were also identified in our study.

Materials and Methods {#s2}
=====================

Study Design and Setting {#s2_1}
------------------------

This retrospective study was performed from January 2015 to December 2017 in the Chongqing Renji Affiliated Hospital of the Chinese Academy of Sciences University, a tertiary university hospital with a 1,800-bed academic medical centre located in Chongqing, Southwest China. Patients with XDR-KP infection were only sensitive to tigecycline or polymyxin B and resistant to all other drugs in this study. To assess for risk factors for XDR-KP infection, a retrospective 1:2 case-control study was performed. The case-control study groups in our analysis were defined as follows: the case group comprised patients with XDR-KP infection during hospitalization, and patients with non-XDR-KP infection at the same site comprised the control group. Patients admitted for \<48 h and those with duplicate isolates were excluded.

Identification and Drug Sensitivity of Bacteria {#s2_2}
-----------------------------------------------

Bacterial cultures were processed in the clinical microbiology laboratory. All the XDR-KP isolates were identified using the VITEK 2 Compact system or the VITEK MS system (bioMérieux, Marcy l'Etoile, Lyon, France), and antimicrobial susceptibilities were determined *in vitro* using a VITEK 2 Compact AST-GN13 card (bioMérieux), which were used to test the antibiotic susceptibilities of all isolates to ampicillin (AMP), ampicillin/sulbactam (SAM), piperacillin (PIR), cefazolin (CFZ), ceftazidime (CAZ), ceftriaxone (CRO), cefepime (FEP), cefoxitin (FOX), aztreonam (AZT), gentamicin (GM), tobramycin (TOB), amikacin (AK), ciprofloxacin (CIP), and levofloxacin (LEV). Five antibiotics, including imipenem (IMP), meropenem (MEM), ertapenem (ETP), tigecycline (TGC) and polymyxin B (PB), were tested by the broth microdilution method following the criteria of the Clinical and Laboratory Standards Institute ([@B9]). The minimal inhibitory concentrations (MICs) breakpoint for tigecycline was defined according to the European Committee on Antimicrobial Susceptibility Testing ([@B13]), while the others were interpreted according to CLSI protocols. *K. pneumoniae* ATCC700603 and *Escherichia coli* ATCC25922 were used as quality control strains for the antibiotic susceptibility tests.

Identification of Resistance Genes {#s2_3}
----------------------------------

Crude DNA extracts were prepared by boiling the bacterial suspensions. This DNA was used as a template in polymerase chain reactions (PCR) to detect antibiotic resistance genes. Standard PCR conditions were used to amplify genes encoding carbapenemase-related genes (*blaKPC*, *blaNDM*, *blaVIM*, *blaIMP*, and *blaOXA*), extended spectrum β-lactamases (*blaTEM*, *blaSHV*, *blaCTX-M-1*, and *blaCTX-M-9*), plasmid-mediated AmpC (*blaEBC*, *blaDHA*, *blaCIT*, *blaCMY*, and *blaMOX*), quinolone resistance determinants (*qnrA*, *qnrB*, *qnrS*, and *acc(6')-Ib-cr*), and aminoglycoside resistance determinants (*armA*, *rmtB*, and *acc(6')-Ib*) using primers and PCR conditions described previously ([@B10]; [@B43]; [@B1]). The sequence of all primers used in this study was listed in [**Table S1**](#SM1){ref-type="supplementary-material"}. The PCR amplicons of carbapenemase, extended spectrum β-lactamases (ESBLs) and AmpC resistance genes were sequenced and the sequences were analyzed on the National Center for Biotechnology Information (NCBI) website.

Data Collection and Definitions {#s2_4}
-------------------------------

After patients in both the case and control groups had been confirmed, relevant demographics and clinical data of the enrolled patients were collected from the electronic medical records and clinical microbiology laboratory databases. Survivor and nonsurvivor subgroups were compared to identify predictors of 28-day mortality.

### Variables {#s2_4_1}

Thirty-six clinical variables were applied in the analysis of the risk factors. The following parameters were used: (1) demographics (age, sex, hospital transfer, intensive care unit admission, and 28-day mortality); (2) baseline diseases and acquired infection (hypertension, diabetes, severe anemia, hypoproteinemia, hypokalemia, septic shock and solid tumors, respiratory, liver, gastrointestinal, cardiovascular, renal, and endocrine system diseases, as well as pulmonary, intra-abdominal, and urinary tract infection); (3) invasive procedures during the hospital stay (parenteral nutrition, mechanical ventilation, urinary catheter, tracheal cannula, drainage tube, previous surgery in the past 6 months, central venous catheter, and arterial catheter); and (4) antibiotic exposure within 3 months (cephalosporins, carbapenem, aminoglycosides, quinolones, tetracyclines, macrolides, metronidazole, and glycopeptides). These variables were analyzed to identify risk factors for XDR-KP infection.

### Definitions {#s2_4_2}

The following terms were defined prior to data analysis. Patients \>65 years old were defined as elderly. Severe anemia was defined as a hemoglobin level \<60 g/L. Hypoproteinemia was defined as serum total protein level \<60 g/L or albumin level \<25 g/L. Hypokalemia was defined as a serum potassium level \<3.5 mmol/L. Septic shock was defined as sepsis associated with organ dysfunction and accompanied by persistent hypotension after volume replacement ([@B42]; [@B21]). The source of infection was determined to be pneumonia, urinary tract infection (UTI), surgical site infection, intra-abdominal infection, or line-related infection using definitions from the US Centers for Disease Control and Prevention (CDC) ([@B24]).

Multilocus Sequence Typing {#s2_5}
--------------------------

Molecular typing was performed by multilocus sequence typing (MLST). The *K. pneumoniae* MLST scheme used internal fragments of the following seven housekeeping genes: beta-subunit of RNA polymerase (*rpoB*), glyceraldehyde 3-phosphate dehydrogenase (*gapA*), malate dehydrogenase (*mdh*), phosphoglucose isomerase (*pgi*), phosphorine E (*phoE*), translation initiation factor 2 (*infB*), and periplasmic energy transducer (*tonB*). The housekeeping genes primer sequence of *K. pneumoniae* was shown in [**Table S2**](#SM1){ref-type="supplementary-material"}. The PCR conditions were queried, and data were analyzed using the *K. pneumoniae* MLST website (<http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html>) ([@B23]; [@B26]; [@B47]).

Sample Size Calculations and Statistical Analysis {#s2_6}
-------------------------------------------------

Based on the report of the CHINET Antimicrobial Resistance Surveillance Program in 2015 ([@B17]), we assumed that XDR-KP will comprise 2.2% of the cases and non-XDR-KP controls will comprise 14.1%. To determine a difference at the 0.05 significance level with 80% power, we estimated that we would need at least 66 XDR-KP vs. 132 non-XDR-KP control cases (EpiInfo, version 3.3.2).

All statistical analyses were performed using SPSS version 23.0 for Windows (SPSS, Inc., Chicago, IL, USA). Categorical variables were presented as frequencies and percentages. In the analysis of risk factors for XDR-KP infection and mortality, the univariate analysis was used for each variable. To identify the independent risk factors, variables with P \< 0.10 in the univariate analysis were included in the logistic regression model for the multivariate analysis and analyzed using backward stepwise regression. The odds ratio (OR) and 95% confidence interval (CI) were also calculated to evaluate the strength of any association that emerged. For all statistical analyses, P \< 0.05 indicated statistical significance.

Results {#s3}
=======

Bacterial Isolates {#s3_1}
------------------

In this study, a total of 69 consecutive nonduplicate XDR-KP isolates were identified from January 2015 to December 2017 and investigated. Isolates originated from different anatomical sites: sputum (n = 21, 30.4%), urine (n = 17, 24.6%), blood (n = 9, 13.0%), bile (n = 7, 10.1%), secretions (n = 5, 7.2%), pus (n = 5, 7.2%), puncture fluid (n = 4, 5.8%), and cannula (n = 1, 1.4%). The majority of patients were in the intensive care unit (n = 23, 33.3%), followed by patients on the hepatobiliary surgical ward (n = 18, 26.1%), respiratory ward (n = 13, 18.8%), urinary surgery ward (n = 7, 10.1%), digestive medicine ward (n = 4, 5.8%), endocrine ward (n = 3, 4.3%) and obstetrics and gynecology ward (n = 1, 1.4%). A total of 138 patients with non-XDR-KP infection were randomly matched in a ratio of 1:2 as the control group. Therefore, 207 patients were included in the final study cohort.

Antibiotic Susceptibility Test {#s3_2}
------------------------------

As shown in [**Table 1**](#T1){ref-type="table"}, all 69 XDR-KP isolates were resistant to common clinical antibacterial drugs including carbapenems, by *in vitro* drug sensitivity tests but were only sensitive to tigecycline and polymyxin B (sensitivity rate 100%). The resistance rate of strains in the XDR-KP infection group was significantly higher than that in the control group, and the difference was statistically significant (P \< 0.05).

###### 

The antimicrobial susceptibility of extensively drug-resistant *Klebsiella pneumoniae* (XDR-KP) and non-XDR-KP.

  Antibiotics            XDR-KP (n = 69)   non-XDR-KP (n = 138)   *P*-value                                        
  ---------------------- ----------------- ---------------------- ----------- ------------ ---------- ------------ -------------
  Ampicillin             0 (0)             0 (0)                  69 (100)    15 (10.9)    4 (2.9)    119 (86.2)   **0.004**
  Ampicillin/sulbactam   0 (0)             0 (0)                  69 (100)    70 (50.8)    2 (1.4)    66 (47.8)    **\<0.001**
  Piperacillin           0 (0)             0 (0)                  69 (100)    77 (55.8)    8 (5.8)    53 (38.4)    **\<0.001**
  Cefazolin              0 (0)             0 (0)                  69 (100)    55 (39.9)    5 (3.6)    78 (56.5)    **\<0.001**
  Ceftriaxone            0 (0)             0 (0)                  69 (100)    93 (67.4)    3 (2.2)    42 (30.4)    **\<0.001**
  Ceftazidime            0 (0)             0 (0)                  69 (100)    94 (68.1)    4 (2.9)    40 (29.0)    **\<0.001**
  Cefepime               0 (0)             0 (0)                  69 (100)    104 (75.4)   8 (5.8)    26 (18.8)    **\<0.001**
  Cefoxitin              0 (0)             0 (0)                  69 (100)    101 (73.2)   5 (3.6)    32 (23.2)    **\<0.001**
  Aztreonam              0 (0)             0 (0)                  69 (100)    68 (49.2)    11 (8.0)   59 (42.8)    **\<0.001**
  Ciprofloxacin          0 (0)             0 (0)                  69 (100)    87 (63.0)    0 (0.0)    51 (37.0)    **\<0.001**
  Levofloxacin           0 (0)             0 (0)                  69 (100)    91 (65.9)    4 (2.9)    43 (31.2)    **\<0.001**
  Gentamicin             0 (0)             0 (0)                  69 (100)    90 (65.2)    7 (5.1)    41 (29.7)    **\<0.001**
  Tobramycin             0 (0)             0 (0)                  69 (100)    104 (75.4)   8 (5.8)    26 (18.8)    **\<0.001**
  Amikacin               0 (0)             0 (0)                  69 (100)    118 (85.5)   5 (3.6)    15 (10.9)    **\<0.001**
  Ertapenem              0 (0)             0 (0)                  69 (100)    126 (91.4)   2 (1.4)    10 (7.2)     **\<0.001**
  Imipenem               0 (0)             0 (0)                  69 (100)    129 (93.5)   0 (0)      9 (6.5)      **\<0.001**
  Meropenem              0 (0)             0 (0)                  69 (100)    129 (93.5)   0 (0)      9 (6.5)      **\<0.001**
  Tigecycline            69 (100)          0 (0)                  0 (0)       138 (100)    0 (0)      0 (0)        **--**
  Polymyxin B            69 (100)          0 (0)                  0 (0)       138 (100)    0 (0)      0 (0)        **--**

Values are presented as n (%), unless otherwise noted. S, susceptible; I, intermediate-resistant; R, resistant. "--" indicates data not available. Bold face indicates values that are significant (P \< 0.05).

Detection of Drug Resistance Genes and ST Types {#s3_3}
-----------------------------------------------

The distribution of resistance genes and ST types are listed in [**Table 2**](#T2){ref-type="table"}. Overall, these XDR-KP isolates had a high prevalence rate of carbapenemase-related resistance genes (n = 66, 95.7%), and only three strains were not determined to have carbapenemase-related resistance genes. Among them, the *KPC-2* gene was mainly carried (n = 52, 75.4%), followed by the *NDM* (n = 21, 30.4%) and *IMP* (n = 5, 7.2%) genes. The *OXA-48* gene was also detected in three XDR-KP strains in our study. Notably, several isolates were determined to carry two carbapenemase-related resistance genes at the same time (n = 15, 21.7%). In addition, all the XDR-KP isolates contained multiple drug resistance genes, including extended spectrum β-lactamases (ESBLs), AmpC β-lactamases, quinolone resistance determinants, and aminoglycoside resistance determinants. Among them, *CTX-M-9* (n = 38, 55.1%), *DHA* (n = 29, 42.0%), *qnrS* (n = 40, 57.9%) and *acc (6')-Ib* (n = 43, 62.3%) were the most frequently detected genes among these drug resistance genes, respectively.

###### 

Distribution of resistance genes and MLST types of extensively drug-resistant *Klebsiella pneumoniae* (XDR-KP).

  Microorganism(no. of strains)   Resistance genes and MLST types (no. of strains)   ST types                                                                 
  ------------------------------- -------------------------------------------------- ---------------- ---------------------- ------------------- ------------ -----------
  XDR-KP (69)                     *KPC-2* (52)                                       *CTX-M-1* (17)   *DHA* (29)             *qnrA* (12)         *armA* (3)   ST11 (58)
  *NDM-1* (16)                    *CTX-M-9* (38)                                     *CMY* (14)       *qnrB* (19)            *rmtB* (36)         ST20 (5)     
  *NDM-5* (5)                     *TEM-1* (28)                                       *MOX* (16)       *qnrS* (40)            *acc(6')-Ib* (43)   ST45 (1)     
  *IMP-4* (4)                     *SHV-2* (6)                                                         *acc(6')-Ib-cr* (28)                       ST592 (2)    
  *IMP-8* (1)                     *SHV-11* (10)                                                                                                  ST661 (2)    
  *OXA-48* (3)                    *SHV-12* (18)                                                                                                  ST751 (1)    

MLST, multilocus sequence typing; ESBL, extended-spectrum β-lactamase.

Drug resistance genes can be transmitted horizontally among bacteria through mobile DNA elements, such as plasmids and integron genes. Molecular typing can assist in the analysis of transmission pathways between bacterial pathogens. The results of MLST showed that six different ST types were identified, of which ST11 was the most predominant epidemic type (n = 58, 84.1%). Perhaps more significantly, all strains of the ST11 type harbored the *KPC-2* gene, which indicated that the *KPC-2* gene was closely related to the prevalence of the XDR-KP strain.

Risk Factor Analysis of XDR-KP Infection {#s3_4}
----------------------------------------

Univariate analysis of the demographics, baseline diseases, acquired infection, invasive procedures, and antibiotic exposure was performed in the case-control groups. The following factors were most frequently associated with the development of XDR-KP infection: ICU admission, transferring from another hospital, respiratory diseases, pulmonary infection, tracheal cannula, and exposure to carbapenem and glycopeptide antibiotics ([**Table 3**](#T3){ref-type="table"}).

###### 

Univariate analysis of risk factors for infection with extensively drug-resistant *Klebsiella pneumoniae* (XDR-KP) and non-XDR-KP.

  Variables                                      XDR-KP infection (n = 69)   Control group (n = 138)   OR (95% CI)         *P-value*
  ---------------------------------------------- --------------------------- ------------------------- ------------------- -------------
  **Demographics**                                                                                                         
  Male gender                                    37 (53.6)                   72 (52.2)                 1.06 (0.59--1.89)   0.844
  Elderly                                        31 (44.9)                   58 (42.0)                 1.13 (0.63--2.02)   0.691
  ICU admission                                  37 (53.6)                   33 (23.9)                 3.68 (1.99--6.79)   **\<0.001**
  Transferring from another hospital             26 (37.7)                   33 (23.9)                 1.92 (1.03--3.59)   **0.039**
  **Baseline diseases and acquired infection**                                                                             
  Hypertension                                   25 (36.2)                   36 (26.1)                 1.61 (0.87--2.99)   0.131
  Diabetes                                       18 (26.1)                   27 (19.6)                 1.45 (0.73--2.87)   0.284
  Hypoproteinemia                                18 (26.1)                   32 (23.2)                 1.16 (0.60--2.27)   0.646
  Hypokalemia                                    15 (21.7)                   18 (13.0)                 1.85 (0.87--3.95)   0.107
  Severe anemia                                  4 (5.8)                     9 (6.5)                   0.88 (0.26--2.97)   0.839
  Septic shock                                   18 (26.1)                   22 (15.9)                 1.86 (0.92--3.77)   0.081
  Solid tumors                                   23 (33.3)                   38 (27.5)                 1.32 (0.71--2.46)   0.388
  Respiratory diseases                           25 (36.2)                   31 (22.5)                 1.96 (1.04--3.69)   **0.036**
  Liver diseases                                 19 (27.5)                   34 (24.6)                 1.16 (0.60--2.24)   0.652
  Gastrointestinal diseases                      15 (21.7)                   28 (20.3)                 1.09 (0.54--2.21)   0.809
  Cardiovascular diseases                        10 (14.5)                   12 (8.7)                  1.78 (0.73--4.35)   0.202
  Renal diseases                                 15 (21.7)                   35 (25.4)                 0.82 (0.41--1.63)   0.566
  Endocrine system diseases                      6 (8.7)                     20 (14.5)                 0.56 (0.21--1.47)   0.235
  Pulmonary infection                            16 (23.2)                   17 (12.3)                 2.15 (1.01--4.57)   **0.044**
  Intra-abdominal infection                      9 (13.0)                    16 (11.6)                 1.14 (0.48--2.74)   0.763
  Urinary tract infection                        10 (14.5)                   23 (16.7)                 0.85 (0.38--1.90)   0.687
  **Invasive procedures during hospital stay**                                                                             
  Parenteral nutrition                           11 (15.9)                   15 (10.9)                 1.56 (0.67--3.59)   0.299
  Mechanical ventilation                         16 (23.2)                   19 (13.8)                 1.89 (0.90--3.96)   0.088
  Urinary catheter                               29 (42.0)                   51 (37.0)                 1.24 (0.69--2.23)   0.481
  Tracheal cannula                               26 (37.7)                   19 (13.8)                 3.79 (1.91--7.53)   **\<0.001**
  Drainage tube                                  8 (11.6)                    23 (16.7)                 0.66 (0.28--1.55)   0.335
  Previous surgery in the past 6 months          24 (34.8)                   38 (27.5)                 1.40 (0.76--2.61)   0.283
  Central venous catheter                        10 (14.5)                   18 (13.0)                 1.13 (0.49--2.60)   0.774
  Arterial catheter                              9 (13.0)                    25 (18.1)                 0.68 (0.29--1.55)   0.353
  **Antibiotic exposure within 3 months**                                                                                  
  Cephalosporins                                 26 (37.7)                   48 (34.8)                 1.13 (0.62--2.06)   0.682
  Carbapenem                                     21 (30.4)                   14 (10.1)                 3.88 (1.82--8.23)   **\<0.001**
  Aminoglycosides                                6 (8.7)                     20 (14.5)                 0.56 (0.22--1.47)   0.235
  Quinolones                                     12 (17.4)                   28 (20.3)                 0.83 (0.39--1.75)   0.619
  Tetracyclines                                  4 (5.8)                     6 (4.3)                   1.35 (0.37--4.97)   0.647
  Macrolides                                     5 (7.2)                     8 (5.8)                   1.27 (0.39--4.04)   0.685
  Metronidazole                                  18 (26.1)                   25 (18.1)                 1.59 (0.80--3.18)   0.183
  Glycopeptides                                  12 (17.4)                   11 (8.0)                  2.43 (1.01--5.84)   **0.042**

Values are presented as n (%), unless otherwise noted. Bold face indicates values that are significant (P \< 0.05). "--" indicates data not available.

ICU, intensive care unit.

Multivariate Analysis of XDR-KP Infection {#s3_5}
-----------------------------------------

The results of the logistic regression analysis of XDR-KP infection are shown in [**Table 4**](#T4){ref-type="table"}: ICU admission (OR: 3.28, 95% CI: 1.66--6.49, *P* \< 0.001), tracheal cannula (OR: 3.16, 95% CI: 1.48--6.76, *P* = 0.003), and carbapenem exposure (OR: 3.16, 95% CI: 1.25--7.98, *P* = 0.015) were identified as independent risk factors for infection with XDR-KP when compared with the control group.

###### 

Multivariate analysis of risk factors for infection with extensively drug-resistant *Klebsiella pneumoniae* (XDR-KP) and non-XDR-KP.

  Variables             B      S.E    Wals    OR     95% CI       *P-value*
  --------------------- ------ ------ ------- ------ ------------ -------------
  ICU admission         1.19   0.35   11.60   3.28   1.66--6.49   **\<0.001**
  Tracheal cannula      1.15   0.39   8.84    3.16   1.48--6.76   **0.003**
  Carbapenem exposure   1.15   0.47   5.90    3.16   1.25--7.98   **0.015**

Bold face indicates values that are significant (P \< 0.05). ICU, intensive care unit.

Risk Factors for 28-Day Mortality {#s3_6}
---------------------------------

At 28 days after infection onset, 21 of the 69 patients we investigated had died. Our study highlights the high mortality associated with XDR-KP infection, as shown in [**Table 5**](#T5){ref-type="table"}. The univariate analysis revealed that the presence of solid tumors, septic shock, and a tracheal cannula resulted in significant differences between the survivor and nonsurvivor groups. Multivariate logistic regression analysis showed that the predictors independently associated with 28-day mortality were solid tumors (OR: 7.22, 95% CI: 1.84--28.34, *P* = 0.005), and septic shock (OR: 9.46, 95% CI: 2.00--44.72, *P* = 0.005).

###### 

Risk factors associated with 28-day mortality.

  Variables                               Nonsurvivors (n = 21)   Survivors (n = 48)   OR (95% CI)          *P*-value     OR (95% CI)          *P*-value
  --------------------------------------- ----------------------- -------------------- -------------------- ------------- -------------------- -----------
  Elderly                                 10 (47.6)               21 (43.8)            1.17 (0.42--3.27)    0.766         **--**               **--**
  ICU admission                           9 (42.9)                28 (58.3)            0.54 (0.19--1.51)    0.236         **--**               **--**
  Solid tumors                            14 (66.7)               9 (18.8)             8.67 (2.71--27.68)   **\<0.001**   7.22 (1.84--28.34)   **0.005**
  Respiratory diseases                    9 (42.9)                16 (33.3)            1.50 (0.52--4.30)    0.449         **--**               **--**
  Digestive system disease                7 (33.3)                12 (25.0)            1.50 (0.49--4.59)    0.476         **--**               **--**
  Urinary System Diseases                 3 (14.3)                12 (25.0)            0.50 (0.13--1.99)    0.321         **--**               **--**
  Cardiovascular diseases                 4 (19.0)                6 (12.5)             1.65 (0.41--6.58)    0.477         **--**               **--**
  Hypoproteinemia                         8 (38.1)                10 (20.8)            2.34 (0.76--7.19)    0.133         **--**               **--**
  Hypokalemia                             7 (33.3)                8 (16.7)             2.50 (0.77--8.16)    0.122         **--**               **--**
  Septic shock                            11 (52.4)               7 (14.6)             6.44 (1.99--20.82)   **\<0.001**   9.46 (2.00--44.72)   **0.005**
  Parenteral nutrition                    3 (14.3)                8 (16.7)             0.83 (0.20--3.51)    0.804         **--**               **--**
  Tracheal cannula                        12 (57.1)               14 (29.2)            3.24 (1.12--9.39)    **0.027**     **--**               **--**
  Drainage tube                           2 (9.5)                 6 (12.5)             0.74 (0.14--3.99)    0.722         **--**               **--**
  Previous surgery in the past 6 months   6 (28.6)                18 (37.5)            0.67 (0.22--2.03)    0.474         **--**               **--**
  Central venous catheter                 3 (14.3)                7 (14.6)             0.98 (0.23--4.21)    0.974         **--**               **--**
  Arterial catheter                       3 (14.3)                6 (12.5)             1.17 (0.26--5.19)    0.839         **--**               **--**
  Mechanical ventilation                  8 (38.1)                8 (16.7)             4.39 (1.35--14.28)   0.052         **--**               **--**
  Cephalosporins                          9 (42.9)                17 (35.4)            1.37 (0.48--3.89)    0.557         **--**               **--**
  Carbapenem                              7 (33.3)                14 (29.2)            1.21 (0.40--3.65)    0.729         **--**               **--**
  Aminoglycosides                         2 (9.5)                 4 (8.3)              1.16 (0.20--6.87)    0.872         **--**               **--**
  Quinolones                              4 (19.0)                8 (16.7)             1.18 (0.31--4.44)    0.810         **--**               **--**
  Macrolides                              1 (4.8)                 4 (8.3)              0.55 (0.06--5.24)    0.599         **--**               **--**

Values are presented as n (%), unless otherwise noted. Bold face indicates values that are significant (P \< 0.05). "--" indicates data not available.

ICU, intensive care unit.

Discussion {#s4}
==========

At present, the emergence and dissemination of the XDR-KP strain is a major worldwide source and shuttle for antibiotic resistance. The increasing prevalence and global spread of these clinically extensively drug-resistant strains gravely threatens public health ([@B32]). According to the global epidemic trend of XDR-KP strains, the detection rate of XDR-KP strains in the northeastern United States, Italy, Greece, Israel and other European countries was relatively high, and there were even reports of local epidemic outbreaks in some areas ([@B55]; [@B20]). However, molecular epidemiological characteristics differ from region to region ([@B19]; [@B28]). To our knowledge, there have been no reports on the epidemiology of and risk factors for XDR-KP infection in Southwestern China. This retrospective study was the first to systematically analyze the clinical characteristics, molecular epidemiology, risk factors of XDR-KP infection and the predictors of mortality.

For the drug sensitivity of XDR-KP strains, only tigecycline and polymyxin B still showed favorable *in vitro* drug sensitivity tests, and they were the most sensitive antibiotics for XDR-KP infection in the present study (sensitivity rate 100%). Currently, tigecycline and polymyxin B are considered to be the last line of defense against XDR-KP infection ([@B44]; [@B7]; [@B3]). However, increasing resistance is reported worldwide, in particular due to the plasmid-encoded protein *mcr-1* present in pathogens such as *Escherichia coli* and *Klebsiella pneumoniae*, which further increases the difficulty of anti-infective treatment ([@B53]; [@B46]). Focusing on the molecular detection and genetic characterization of XDR-KP strains, we found that all the XDR-KP isolates contained multiple drug resistance genes, suggesting that the wide resistome of strains was related to the plentiful chromosomal and plasmid-encoded antibiotic resistance genes. The data revealed that the emergence of carbapenemase genes and ESBLs was the primary resistance mechanism. Among them, *KPC-2* and *CTX-M-9* group genes were the most prevalent in this study and were reported to be the most easily transmitted horizontally in KP ([@B16]; [@B40]; [@B49]). In addition, *DHA* was reported to be the most common gene in KP producing AmpC β-lactamases in many studies, which was consistent with our study ([@B2]; [@B25]). Notably, under antibiotic selective pressure, the pathogen continuously accumulates multiple drug resistance genes by acquiring plasmids and transferable genetic elements, ultimately leading to XDR strains harboring a 'super resistome' ([@B39]).

MLST could be used to understand the epidemiology at a large scale in local outbreak situations. In the current study, ST11 was the most predominant epidemic type among the six different ST types identified, concordant with the report that ST11 was the major sequence type in Mainland China ([@B15]; [@B50]), and different from the international hyper-epidemic lineage ST258. Previous studies have shown that the hyperepidemic clonal complex of multidrug-resistant *K. pneumoniae* in ST258 clone may be spreading in the north-eastern region of Hungary ([@B48]), which were different from our results. Interestingly, only one of the seven housekeeping genes between ST11 (*gapA*, *infB*, *mdh*, *pgi*, *phoE*, *rpoB*, *tonB*: 3, 3, 1, 1, 1, 1, 4) and ST258 (*gapA*, *infB*, *mdh*, *pgi*, *phoE*, *rpoB*, *tonB*: 3, 3, 1, 1, 1, 1, 79) was different, suggesting that they were closely related to each other ([@B51]). Notably, all strains of ST11 XDR-KP isolates harbored the *KPC-2* gene in our study, suggesting that the *KPC-2* gene was involved in the epidemic dissemination of XDR-KP strains, which has frequently been reported worldwide in the interspecific transmission and dissemination of *Enterobacteriaceae* ([@B18]). If not effectively controlled, the ST11 clone could possibly spread widely in the future and even lead to the outbreak of XDR-KP strains.

Univariate analyses revealed that ICU admission, transferring from another hospital, respiratory diseases, pulmonary infection, tracheal cannula and exposure to carbapenem and glycopeptide antibiotics were strongly correlated with XDR-KP infection, which has also been identified by other studies. In addition, ICU admission, tracheal cannula, and carbapenem exposure were identified as independent risk factors for infection with XDR-KP in our study. Moreover, these ICU patients with concomitant infections had more severe underlying diseases and lower immunity, which might have made them more vulnerable to acquiring XDR-KP infection, and invasive procedures such as tracheal cannula and mechanical ventilation would have increased the possibility of drug-resistant bacteria adhesion, which ultimately led to infection with XDR-KP strains ([@B27]; [@B31]). In addition, the selection pressure of antibiotics played an important role in the development of multiple drug resistance of bacteria. It was generally believed that under the pressure of carbapenem, susceptible strains were inhibited or killed, leading to the proliferation of many drug-resistant strains as dominant bacteria. Moreover, drug-resistant genes carried by drug-resistant bacteria could have been transmitted horizontally to susceptible strains by the acquisition of plasmids and transferable genetic elements, thus causing more serious epidemics of drug-resistant bacteria ([@B29]; [@B35]; [@B52]). Therefore, we should select antibiotics according to drug sensitivity test results, and the abuse of carbapenem antibiotics should be avoided to reduce the production of XDR-KP strains.

Our study highlights the high mortality associated with XDR-KP infection. We found that solid tumors and septic shock were independent risk factors for death caused by XDR-KP infection. Most cancer patients usually have low immunity after radiotherapy or chemotherapy. After infection with "superbacteria" such as XDR-KP, these patients often received inappropriate initial antimicrobial treatment, which might damage prognosis and increase mortality. In addition, drug-resistant bacteria often cause serious infections, resulting in bacteremia or even sepsis in patients, causing septic shock that leads to multiple organ failure or even death ([@B14]; [@B8]; [@B36]). Therefore, the surveillance of cancer and septic shock patients infected with XDR-KP should be strengthened to reduce their mortality.

Limitations {#s4_1}
-----------

Given that this was a retrospective, case-control study, it is not possible to determine the absolute risk associated with the identified risk factors. In addition, this retrospective study was conducted at a single medical centre, and our sample size was relatively small, which might have led to errors in statistical analysis and the omission of some other risk factors.

Conclusions {#s5}
===========

This retrospective study was the first to systematically analyze the clinical characteristics, molecular epidemiology, and risk factors of XDR-KP infection and the predictors of mortality. Our findings showed that ST11 was the predominant epidemic type of XDR-KP producing *KPC-2* in Southwestern China. In addition, ICU admission, tracheal cannula, and carbapenem exposure were identified as independent risk factors for infection with XDR-KP in this study. Moreover, another important finding of this study was that solid tumors and septic shock were independent risk factors for death caused by XDR-KP infection. Therefore, physicians should be aware of these high-risk patients with notable predictive factors for XDR-KP infection to reduce their mortality rate.
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